Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus

Journal of Infectious Diseases

Volumn 193, Issue 12, 2006, Pages 1666-1676

  Olive, Colleen ^a,b   Ho, Mei Fong ^a   Dyer, Joanna ^a   Lincoln, Douglas ^a   Barozzi, Nadia ^a   Toth, Istvan ^a   Good, Michael F ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID CORE PEPTIDE VACCINE; STREPTOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ABORIGINE; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; IMMUNE RESPONSE; IMMUNIZATION; INFECTION PREVENTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS GROUP A; STREPTOCOCCUS INFECTION; VIRUS STRAIN;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; CARRIER PROTEINS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; IMMUNOGLOBULIN G; LIPIDS; MICE; MICROSCOPY, FLUORESCENCE; MOLECULAR STRUCTURE; OPSONIN PROTEINS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCAL VACCINES; STREPTOCOCCUS PYOGENES; SURVIVAL ANALYSIS; VACCINES, SUBUNIT;

EID: 33744815597     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/504266     Document Type: Article

References (25)

1. Carapetis JR. A review of WHO activities in, the burden of, and the evidence for strategies to control group A streptococcal diseases. Part III. The current evidence for the burden of group A streptococcal diseases. Melbourne: University of Melbourne, 2004:1.
2. Carapetis JR, Wolff DR, Currie BJ. Acute rheumatic fever and rheumatic heart disease in the top end of Australia's Northern Territory. Med J Aust 1996; 164:146-9.
3. Fischetti V. Streptococcal M protein. Sci Am 1991; 264:32-9.
4. Beachey EH, Seyer JM, Dale JB. Type-specific protective immunity evoked by synthetic peptide of Streptococcus pyogenes M protein. Nature 1981; 292:457-9.
5. Dale JB, Beachey EH. Localization of protective epitopes of the amino terminus of type 5 streptococcal M protein. J Exp Med 1986; 163:1191-202.
6. Hall MA, Stroop SD, Hu MC, et al. Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections. Infect Immun 2004; 72:2507-12.
7. Hu MC, Walls MA, Stroop SD, Reddish MA, Beall B, Dale JB. Immunogenicity of a 26-valent group A streptococcal vaccine. Infect Immun 2002; 70:2171-7.
8. Bessen D, Fischetti VA. Synthetic peptide vaccine against mucosal colonization by group A streptococci. J Immunol 1990; 145:1251-6.
9. Bronze MS, Courtney HS, Dale JB. Epitopes of group A streptococcal M protein that evoke cross-protective local immune responses. J Immunol 1992; 148:888-93.
10. Olive C, Batzloff MR, Horváth A, et al. Immunisation of mice with a lipid core peptide construct containing a conserved region determinant of group A streptococcal M protein elicits heterologous opsonic antibodies in the absence of adjuvant. Infect Immun 2002; 70:2734-8.
11. Batzloff MR, Hayman WA, Davies MR, et al. Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8- and diphtheria toxoid-specific antibodies to protection. J Infect Dis 2003; 187:1598-608.
12. Olive C, Clair T, Yarwood P, Good MF. Protection of mice from group A streptococcal infection by intranasal immunization with a peptide that contains a conserved M protein B-cell epitope and lacks a T-cell autoepitope. Vaccine 2002; 20:2816-25.
13. Bessen D, Fischett VA. Influence of intranasal immunisation with synthetic peptides corresponding to conserved epitopes of M protein on mucosal colonisation by group A streptococci. Infect Immun 1988; 56:2666-72.
14. Fischetti VA, Hodges VM, Hruby DE. Protection against streptococcal pharyngeal colonization with a vaccinia: M protein recombinant. Science 1989; 244:1487-90.
15. Mannam P, Jones KF, Geller BL. Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes. Infect Immun 2004; 72:3444-8.
16. Brandt ER, Sriprakash KS, Hobb RL, et al. Novel multi-epitope strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population. Nature Medicine 2000; 6:455-9.
17. Olive C, Batzloff MR, Horváth A, et al. Potential of lipid core peptide technology as a novel self-adjuvanting vaccine delivery system for multiple different synthetic peptide immunogens. Infect Immun 2003; 71:2373-83.
18. Horvath A, Olive C, Sun HK, Good MF, Toth I. Towards the development of a synthetic group A streptococcal vaccine of high purity and broad protective coverage. J Med Chem 2004; 47:4100-4.
19. Toth I, Danton M, Flinn N, Gibbons WA. A combined adjuvant and carrier system for enhancing synthetic peptides immunogenicity utilising lipidic amino acids. Tetrahedron Lett 1993; 34:3925-8.
20. Cunningham MW, Antone SM, Smart M, Liu R, Kosanke S. Molecular analysis of human cardiac myosin-cross-reactive B- and T-cell epitopes of the group A streptococcal M5 protein. Infect Immun 1997; 65:3913-23.
21. Dale JB, Beachey EH. Sequence of myosin-cross-reactive epitopes of streptococcal M protein. J Exp Med 1986; 164:1785-8.
22. Pruksakorn S, Currie B, Brandt E, et al. Identification of T cell autoepitopes that cross-react with the C-terminal segment of the M protein of group A streptococci. Int Immunol 1994; 6:1235-44.
23. Hayman WA, Brandt ER, Reif WA, Cooper J, Saul A, Good MF. Mapping the minimal murine T cell and B cell epitopes within a peptide vaccine candidate from the conserved region of the M protein of group A streptococcus. Int Immunol 1997; 9:1723-33.
24. Relf WA, Cooper J, Brandt ER, et al. Mapping a conserved conformational epitope from the M protein of group A streptococci. Peptide Research 1996; 9:12-20.
25. Brandt ER, Hayman WA, Currie B, Pruksakorn S, Good MF. Human antibodies to the conserved region of the M protein: opsonization of heterologous strains of group A streptococci. Vaccine 1997; 15:1805-12.